Temasek-Led €255M Investment Round in ITM Isotope Technologies Munich SE

Telix Pharmaceuticals Acquires ARTMS Inc.

March 5, 2024

Pharmaceuticals

Telix Pharmaceuticals Limited has completed the acquisition of ARTMS Inc., a Burnaby, British Columbia-based developer of cyclotron-based isotope production technology and the QUANTM Irradiation System (QIS). The deal strengthens Telix's vertical integration and supply-chain control for key diagnostic and therapeutic radioisotopes (including 89Zr, 68Ga, 99mTc and 64Cu) to support its commercial products and pipeline.

Temasek Acquires Element Materials Technology from Bridgepoint

January 25, 2022

Industrial Services

Temasek has completed the acquisition of Element Materials Technology, a global testing, inspection and certification (TIC) group, from private equity owner Bridgepoint. Headquartered in London with over 7,000 employees and annual revenues above $1 billion, Element will partner with Temasek to accelerate growth and deepen capabilities in high-growth end-markets such as life sciences and connected technologies.

Charme Capital Partners Acquires Majority Stake in Tema Sinergie

October 27, 2022

Medical Devices

Charme Capital Partners (through its Charme IV fund) will acquire a majority stake in Tema Sinergie S.p.A., an Italian manufacturer of isolators and filling/inspection systems for nuclear medicine and biotech pharmaceutical production. The investment will support Tema Sinergie's international expansion, product innovation and growth in theragnostic and biotech segments while preserving management continuity under CEO Stefano Piancastelli.

EQT Acquires Mabtech from IK Partners and Mérieux Equity Partners

January 9, 2024

Biotechnology

EQT, via its newly launched EQT Healthcare Growth Strategy, is acquiring Swedish immunoassay specialist Mabtech AB from IK Partners and Mérieux Equity Partners. Mabtech, a developer and manufacturer of antibodies, kits and readers used in vaccine, infectious disease and oncology research, will be supported by EQT to expand its product portfolio and accelerate geographic growth, particularly in the US. The transaction is subject to customary regulatory approvals and financial terms were not disclosed.

Telix Pharmaceuticals Acquires QSAM Biosciences

February 8, 2024

Biotechnology

Telix Pharmaceuticals Limited has entered into an agreement to acquire QSAM Biosciences, Inc., adding QSAM's lead radiopharmaceutical candidate 153Sm-DOTMP (Samarium-153-DOTMP) to Telix's therapeutic pipeline. The asset expands Telix's oncology focus into bone-targeting radiopharmaceuticals with potential applications in pain management of bone metastases and osteosarcoma (including pediatric indications).

Lumera Acquires ITM from Inflexion

July 1, 2024

Financial Services

Sweden-based, private equity‑backed insurtech Lumera has acquired ITM, a UK data services and technology specialist for the pensions market, from Inflexion. ITM provides proprietary software and technology‑enabled services including data audit, management, administration and migration and was supported by Inflexion through M&A and international expansion. Lumera says the deal strengthens its UK presence and complements its life & pensions technology and data services portfolio.